Amphetamine; amphetamine aspartate/dextroamphetamine sulfate - Generic Drug Details

What are the generic sources for amphetamine; amphetamine aspartate/dextroamphetamine sulfate and what is the scope of freedom to operate?

Amphetamine; amphetamine aspartate/dextroamphetamine sulfate is the generic ingredient in five branded drugs marketed by Tris Pharma Inc and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amphetamine; amphetamine aspartate/dextroamphetamine sulfate has twenty-one patent family members in fourteen countries.

One supplier is listed for this compound.

Summary for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

International Patents:	21
US Patents:	10
Tradenames:	5
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	amphetamine; amphetamine aspartate/dextroamphetamine sulfate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Constraining patent/regulatory exclusivity:

9,675,703

Dosage:

SUSPENSION, EXTENDED RELEASE;ORAL

Constraining patent/regulatory exclusivity:

8,337,890

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DYANAVEL XR 5	Extended-release Tablets	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	5 mg, 10 mg, 15 mg and 20 mg	210526	1	2025-01-22

US Patents and Regulatory Information for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Tris Pharma Inc	DYANAVEL XR	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	SUSPENSION, EXTENDED RELEASE;ORAL	208147-001	Oct 19, 2015		RX	Yes	Yes	8,883,217		Y
Tris Pharma Inc	DYANAVEL XR 5	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	TABLET, EXTENDED RELEASE;ORAL	210526-001	Nov 4, 2021		RX	Yes	No	8,747,902		Y
Tris Pharma Inc	DYANAVEL XR	amphetamine; amphetamine aspartate/dextroamphetamine sulfate	SUSPENSION, EXTENDED RELEASE;ORAL	208147-001	Oct 19, 2015		RX	Yes	Yes	8,062,667		Y

International Patents for amphetamine; amphetamine aspartate/dextroamphetamine sulfate

Country	Patent Number	Title	Estimated Expiration
Israel	194042	פורמולציות לשחרור שונה המכילות קומפלקסים של תרופה ורזין מחליף יונים (Modified release formulations containing drug-ion exchange resin complexes)
Japan	5479086
Brazil	PI0709606	suspensão líquida administrável oralmente com características de liberação modificada

Market Dynamics and Financial Trajectory for Amphetamine and Derivatives

Last updated: August 3, 2025

Introduction

Amphetamine, alongside its derivatives such as amphetamine aspartate and dextroamphetamine sulfate, remains a pivotal focus within pharmaceutical, regulatory, and clinical landscapes. The market for these stimulant compounds is complex, driven by medical, regulatory, and societal factors. This article analyzes market dynamics and financial trajectories shaping the future prospects of these substances, emphasizing their regulatory status, clinical applications, manufacturing trends, and commercial opportunities.

Regulatory Landscape and Market Access

The regulatory environment fundamentally influences the market trajectory of amphetamine and its derivatives. Globally, these compounds are classified under controlled substances schedules due to their high potential for abuse and dependence. The United States Drug Enforcement Administration (DEA) classifies dextroamphetamine and physically similar formulations as Schedule II substances, imposing strict manufacturing quotas and distribution controls [1].

In Europe and other jurisdictions, similar classifications restrict prescribing and distribution. Stringent regulations pose barriers to entry, impacting both existing manufacturers and potential market entrants. Conversely, regulatory approvals for specific therapeutic indications—such as ADHD and narcolepsy—are vital for sustaining market access and revenue streams.

Recent regulatory developments include re-evaluation of prescription guidelines, increased oversight of prescribing practices, and tighter supply chain controls, all contributing to potential supply constraints, especially in markets with high abuse potential. Nonetheless, approved formulations remain in steady demand owing to their clinical efficacy.

Clinical Applications and Market Drivers

The primary clinical indications for amphetamine and its derivatives include Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy, and, in some contexts, treatment-resistant depression. The global rise in ADHD diagnoses, especially in children and young adults, has propelled demand for stimulant medications.

According to IQVIA data, the ADHD therapeutic market alone is projected to exhibit a Compound Annual Growth Rate (CAGR) of approximately 4-6% over the next five years [2]. This growth is driven by increased awareness, expanded diagnostic criteria, and improved access to healthcare services.

Moreover, off-label use and misuse concerns influence market dynamics by prompting regulatory scrutiny and affecting prescribing behaviors. The emergence of generic formulations also enhances market competitiveness, potentially reducing prices but expanding volume.

Behavioral therapy and non-stimulant alternatives are modestly influencing the market, yet stimulants like dextroamphetamine sulfate retain dominance due to proven efficacy and familiarity among clinicians.

Manufacturing and Supply Chain Considerations

Manufacturing of amphetamine derivatives involves complex chemical synthesis routes with strict adherence to Good Manufacturing Practices (GMP). Supply chain stability is paramount, considering the high regulatory oversight and potential for diversion or illicit manufacturing.

Recent supply disruptions have historically been linked to regulatory enforcement activities, geopolitical factors, or raw material shortages, constraining availability. To mitigate such risks, some manufacturers are investing in vertical integration and flexible manufacturing capacity.

Emerging trends highlight the adoption of pharmaceutical-grade synthesis methods to improve purity and reduce contamination risks. Intellectual property (IP) rights, although limited due to the expiration of many formulations, influence strategic manufacturing partnerships and licensing agreements.

Market Competition and Commercialization Trends

The competitive landscape includes both branded and generic suppliers. Major players, such as Impax Laboratories, Teva Pharmaceuticals, and Mylan, have a significant share in producing dextroamphetamine sulfate and related formulations. The patent expiration of early formulations has opened avenues for generics, intensifying price competition.

Pricing strategies are influenced by patent status, market demand, and regulatory pressure. While branded formulations command premium prices, market penetration of generics has led to substantial price erosion, creating both opportunities and challenges for revenue maximization.

Furthermore, the advent of abuse-deterrent formulations (ADFs) in recent years aims to address misuse concerns but often entail higher manufacturing costs. The integration of digital health tools, such as prescribing monitoring systems, also influences commercialization strategies by reducing diversion.

Financial Trajectory and Market Outlook

Financially, the amphetamine market remains resilient owing to consistent demand in clinical settings. The global market size for stimulant medications, including amphetamine derivatives, was valued at approximately $2.8 billion in 2022, with a forecast CAGR of 4-5% through 2027 [3].

Key financial drivers include increased prescribing volumes, generic competition, and expanding indications such as adult ADHD. The emergence of exports from established manufacturing hubs like India and China fuels global supply but raises regulatory and quality assurance considerations.

Pricing pressures and regulatory measures could temper revenue growth, but innovation in formulations and expanding market access are expected to offset these challenges. The industry's future trajectory hinges on balancing clinical needs with regulatory compliance, societal concerns, and technological advancements.

Societal and Ethical Considerations

The societal impact of amphetamine use—particularly abuse and diversion—significantly influences market outlooks. Regulatory agencies emphasize control measures to prevent misuse while ensuring legitimate access.

Ethical considerations around addiction, side effects, and equitable access influence policy decisions and market stability. Public health initiatives focused on responsible prescribing and monitoring are critical components shaping future formulations and formulations.

Emerging Opportunities and Challenges

Technological innovations, including long-acting formulations and non-stimulant alternatives, present growth opportunities. Additionally, the development of pharmacogenomic insights to tailor therapies could revolutionize prescribing patterns.

Challenges persist, notably in regulatory compliance, sourcing raw materials, managing societal perceptions, and counteracting illicit markets. Organizations investing in research and development, along with robust regulatory engagement, will likely shape the competitive landscape.

---

Key Takeaways

• Regulatory dynamics dominate market access, with strict controls affecting manufacturing, distribution, and prescribing practices for amphetamine derivatives.
• Clinical demand driven by ADHD prevalence and narcolepsy sustains steady growth, with a projected CAGR of approximately 4-6% over five years.
• Generics and abuse-deterrent formulations intensify competition while addressing societal concerns about misuse.
• Supply chain stability remains vulnerable to regulatory enforcement and geopolitical factors; strategic manufacturing investments are vital.
• Financial outlook remains positive, with industry revenue expected to grow steadily, but pricing pressures and regulatory shifts could influence profitability.

---

FAQs

1. How do regulatory changes impact the pharmaceutical market for amphetamine derivatives?
Regulatory changes impose stricter manufacturing, distribution, and prescribing controls, increasing compliance costs and limiting supply but also aiming to prevent misuse and diversion, which can influence market stability and pricing.

2. What are the main clinical applications of amphetamine and its derivatives?
They primarily treat ADHD and narcolepsy. Growing awareness and expanded diagnostic criteria continue to drive demand, especially as older formulations face patent expiration and generic versions enter the market.

3. How is the manufacturing landscape evolving for these stimulants?
Manufacturers focus on enhanced GMP compliance, raw material sourcing, and developing abuse-deterrent formulations. Supply chain resilience and technological innovations are priorities to meet regulatory standards and maintain steady supply.

4. What are the key competitive factors shaping the market?
Price, regulatory compliance, formulation innovations, and the breadth of approved indications influence competitiveness. Generics are reducing costs, while branded products leverage clinical brand loyalty.

5. What future trends could influence the financial trajectory of this market?
Advancements in personalized medicine, long-acting formulations, and digital health integration. Conversely, regulatory tightening and societal pushback against stimulant misuse could slow growth or reshape market strategies.

---

Sources:

[1] DEA Diversion Control Program, 2022.
[2] IQVIA, Global ADHD Market Report, 2022.
[3] MarketWatch, "Global Stimulant Market Analysis," 2023.